Summary
Global Markets Direct’s, ‘Psychosis - Pipeline Review, H1 2016’, provides an overview of the Psychosis pipeline landscape.
The report provides comprehensive information on the therapeutics under development for Psychosis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Psychosis and features dormant and discontinued projects.
Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.
Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.
Scope
- The report provides a snapshot of the global therapeutic landscape of Psychosis
- The report reviews pipeline therapeutics for Psychosis by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved Psychosis therapeutics and enlists all their major and minor projects
- The report assesses Psychosis therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news related to pipeline therapeutics for Psychosis
Reasons to buy
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of therapeutics under development for Psychosis
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Psychosis pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Companies Mentioned
Acadia Pharmaceuticals Inc.
Addex Therapeutics Ltd
Evotec AG
Gabather AB
Glenmark Pharmaceuticals Ltd.
Heptares Therapeutics Limited
Integrative Research Laboratories Sweden AB
Merck & Co., Inc.
Newron Pharmaceuticals S.p.A.
Reviva Pharmaceuticals Inc.
Sumitomo Dainippon Pharma Co., Ltd.
Sunovion Pharmaceuticals Inc.
Wuhan Docan Pharmaceutical Co., Ltd
'
Table of Contents
Table of Contents 2
List of Tables 5
List of Figures 5
Introduction 6
Global Markets Direct Report Coverage 6
Psychosis Overview 7
Therapeutics Development 8
Pipeline Products for Psychosis - Overview 8
Psychosis - Therapeutics under Development by Companies 9
Psychosis - Pipeline Products Glance 10
Late Stage Products 10
Clinical Stage Products 11
Early Stage Products 12
Psychosis - Products under Development by Companies 13
Psychosis - Companies Involved in Therapeutics Development 14
Acadia Pharmaceuticals Inc. 14
Addex Therapeutics Ltd 15
Evotec AG 16
Gabather AB 17
Glenmark Pharmaceuticals Ltd. 18
Heptares Therapeutics Limited 19
Integrative Research Laboratories Sweden AB 20
Merck & Co., Inc. 21
Newron Pharmaceuticals S.p.A. 22
Reviva Pharmaceuticals Inc. 23
Sumitomo Dainippon Pharma Co., Ltd. 24
Sunovion Pharmaceuticals Inc. 25
Wuhan Docan Pharmaceutical Co., Ltd 26
Psychosis - Therapeutics Assessment 27
Assessment by Monotherapy Products 27
Assessment by Target 28
Assessment by Mechanism of Action 30
Assessment by Route of Administration 32
Assessment by Molecule Type 33
Drug Profiles 34
ADX-88178 - Drug Profile 34
Product Description 34
Mechanism of Action 34
R&D Progress 34
CB-0306 - Drug Profile 36
Product Description 36
Mechanism of Action 36
R&D Progress 36
Drug to Agonize Muscarinic M1 and M4 Receptors for Psychosis and Neurologic Diseases - Drug Profile 37
Product Description 37
Mechanism of Action 37
R&D Progress 37
Drug to Agonize Muscarinic M4 Receptors for Psychiatric Diseases and Alzheimer's Disease - Drug Profile 38
Product Description 38
Mechanism of Action 38
R&D Progress 38
evenamide - Drug Profile 39
Product Description 39
Mechanism of Action 39
R&D Progress 39
Gaaba-002 - Drug Profile 40
Product Description 40
Mechanism of Action 40
R&D Progress 40
IRL-790 - Drug Profile 42
Product Description 42
Mechanism of Action 42
R&D Progress 42
pimavanserin tartrate - Drug Profile 43
Product Description 43
Mechanism of Action 43
R&D Progress 43
RP-5063 - Drug Profile 45
Product Description 45
Mechanism of Action 45
R&D Progress 45
SEP-39 - Drug Profile 46
Product Description 46
Mechanism of Action 46
R&D Progress 46
Small Molecule for Psychosis - Drug Profile 47
Product Description 47
Mechanism of Action 47
R&D Progress 47
Small Molecule to Modulate Metabotropic Glutamate Receptor 2 for Psychosis - Drug Profile 48
Product Description 48
Mechanism of Action 48
R&D Progress 48
Small Molecules to Agonize M1/M4 Muscarinic Acetylcholine Receptors for Psychosis - Drug Profile 49
Product Description 49
Mechanism of Action 49
R&D Progress 49
Small Molecules to Inhibit PDE10A for Schizophrenia and Psychosis - Drug Profile 50
Product Description 50
Mechanism of Action 50
R&D Progress 50
Small Molecules to Inhibit PDE10A for Schizophrenia and Psychosis - Drug Profile 51
Product Description 51
Mechanism of Action 51
R&D Progress 51
Psychosis - Recent Pipeline Updates 52
Psychosis - Dormant Projects 61
Psychosis - Discontinued Products 62
Psychosis - Product Development Milestones 63
Featured News & Press Releases 63
Mar 29, 2016: FDA Advisory Committee Votes 12 to 2 That Benefits of ACADIA Pharmaceuticals’ NUPLAZID(Pimavanserin) for the Treatment of Psychosis Associated with Parkinson’s Disease Outweigh the Risks 63
Jan 29, 2016: ACADIA Pharmaceuticals Announces FDA Advisory Committee Meeting to Review NUPLAZID(Pimavanserin) for the Treatment of Parkinson’s Disease Psychosis 63
Nov 17, 2014: Heptares First-In-Class Selective Muscarinic Agonists Chosen As One Of Top Neuroscience Projects To Watch 64
Sep 02, 2014: Acadia Pharmaceuticals Receives FDA Breakthrough Therapy Designation for NUPLAZID™ (Pimavanserin) for Parkinson’s Disease Psychosis 64
Aug 28, 2014: ACADIA Pharmaceuticals Announces Trade Name NUPLAZID for Pimavanserin 65
Apr 14, 2010: Joseph Friedman To Present Data From ACADIA's First Phase III Trial With Pimavanserin For PDP At 62nd American Academy Of Neurology Annual Meeting 65
Sep 01, 2009: ACADIA Pharmaceuticals Announces Results from Phase III Trial of Pimavanserin in Parkinson's Disease Psychosis 66
May 06, 2009: ACADIA Pharmaceuticals and Biovail Announce Completion of Enrollment in First Pivotal Phase III Trial with Pimavanserin in Patients with Parkinson's Disease Psychosis 66
Jun 11, 2007: ACADIA Pharmaceuticals Initiates Phase III Trial with Pimavanserin in Patients with Parkinson's Disease Psychosis 67
Appendix 68
Methodology 68
Coverage 68
Secondary Research 68
Primary Research 68
Expert Panel Validation 68
Contact Us 68
Disclaimer 69
List of Tables
Number of Products under Development for Psychosis, H1 2016 8
Number of Products under Development by Companies, H1 2016 9
Comparative Analysis by Late Stage Development, H1 2016 10
Comparative Analysis by Clinical Stage Development, H1 2016 11
Comparative Analysis by Early Stage Development, H1 2016 12
Products under Development by Companies, H1 2016 13
Psychosis - Pipeline by Acadia Pharmaceuticals Inc., H1 2016 14
Psychosis - Pipeline by Addex Therapeutics Ltd, H1 2016 15
Psychosis - Pipeline by Evotec AG, H1 2016 16
Psychosis - Pipeline by Gabather AB, H1 2016 17
Psychosis - Pipeline by Glenmark Pharmaceuticals Ltd., H1 2016 18
Psychosis - Pipeline by Heptares Therapeutics Limited, H1 2016 19
Psychosis - Pipeline by Integrative Research Laboratories Sweden AB, H1 2016 20
Psychosis - Pipeline by Merck & Co., Inc., H1 2016 21
Psychosis - Pipeline by Newron Pharmaceuticals S.p.A., H1 2016 22
Psychosis - Pipeline by Reviva Pharmaceuticals Inc., H1 2016 23
Psychosis - Pipeline by Sumitomo Dainippon Pharma Co., Ltd., H1 2016 24
Psychosis - Pipeline by Sunovion Pharmaceuticals Inc., H1 2016 25
Psychosis - Pipeline by Wuhan Docan Pharmaceutical Co., Ltd, H1 2016 26
Assessment by Monotherapy Products, H1 2016 27
Number of Products by Stage and Target, H1 2016 29
Number of Products by Stage and Mechanism of Action, H1 2016 31
Number of Products by Stage and Route of Administration, H1 2016 32
Number of Products by Stage and Molecule Type, H1 2016 33
Psychosis Therapeutics - Recent Pipeline Updates, H1 2016 52
Psychosis - Dormant Projects, H1 2016 61
Psychosis - Discontinued Products, H1 2016 62
List of Figures
Number of Products under Development for Psychosis, H1 2016 8
Number of Products under Development by Companies, H1 2016 9
Comparative Analysis by Clinical Stage Development, H1 2016 11
Comparative Analysis by Early Stage Products, H1 2016 12
Assessment by Monotherapy Products, H1 2016 27
Number of Products by Top 10 Targets, H1 2016 28
Number of Products by Stage and Top 10 Targets, H1 2016 28
Number of Products by Top 10 Mechanism of Actions, H1 2016 30
Number of Products by Stage and Top 10 Mechanism of Actions, H1 2016 30
Number of Products by Stage and Routes of Administration, H1 2016 32
Number of Products by Stage and Molecule Types, H1 2016 33
